The narrow possibilities for coverage of Alzheimer’s disease therapies under the US Centers for Medicare and Medicaid Services’ current coverage decision has eliminated the need to push for a quick accelerated approval of its Alzheimer’s candidate donanemab, Eli Lilly and Company execs told the firm’s fourth quarter and full year 2021 earnings call on 3 February. Instead, Lilly will wait for Phase III data that could be more convincing for payers, practitioners and regulators.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?